UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000045355
Receipt number R000051790
Scientific Title A prospective study on prediction of efficacy of preoperative radiochemotherapy for advanced rectal cancer using liquid biops
Date of disclosure of the study information 2021/09/02
Last modified on 2024/02/01 13:05:59

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A prospective study on prediction of efficacy of preoperative radiochemotherapy for advanced rectal cancer using liquid biops

Acronym

A prospective study on prediction of efficacy of preoperative radiochemotherapy for advanced rectal cancer using liquid biops

Scientific Title

A prospective study on prediction of efficacy of preoperative radiochemotherapy for advanced rectal cancer using liquid biops

Scientific Title:Acronym

A prospective study on prediction of efficacy of preoperative radiochemotherapy for advanced rectal cancer using liquid biops

Region

Japan


Condition

Condition

Advanced Rectal Cancer

Classification by specialty

Gastrointestinal surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

The purpose of this study is threefold. To evaluate the efficacy of preoperative chemoradiation in patients with locally advanced rectal cancer.
1) To determine whether plasma and urine cell free DNA levels and the presence or absence of RAS and p53 mutations are useful for predicting response in pretreatment liquid biopsy.
2) To evaluate whether cell free DNA levels and mutation allele frequency (MAF) in preoperative chemoradiation, at the end of each course, and in postoperative liquid biopsy are predictive of response to nCRT.
(3) To follow the changes of cell free DNA level and MAF in patients with clinical complete response (cCR) and to examine the relationship with relapse and prognosis.

Translated with www.DeepL.com/Translator (free version)

Basic objectives2

Bio-availability

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Others

Developmental phase

Not applicable


Assessment

Primary outcomes

The correlation of the dose of ctDNA and exosome DNA during treatment and the survival.

Key secondary outcomes

Correlation between ctDNA and exosome DNA amounts before, during, and after treatment and recurrence-free survival time
Correlation between ctDNA, exosome DNA amount and tumor markers
Correlation between ctDNA, exosome DNA amount, response rate of neoadjuvant chemotherapy (RECIST Ver1.1), and disease control
Correlation between the amount of ctDNA and exosome DNA and the rate of decrease in the SUVmax value of the primary tumor determined by PET-CT examination
Correlation between ctDNA, exosome DNA amount and histological treatment effect (grade based on tumor cell disappearance rate according to Evans criteria)
Correlation between ctDNA, exosome DNA amount and resection rate
ctDNA, exosome DNA amount and radical resection rate (R1 or R0; R1: state with no macroscopic residual cancer, R0: state with no histological residual cancer)
Comparative study of the amount of ctDNA and exosome DNA of the target gene and immunostaining results in surgical resection specimens


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

90 years-old >=

Gender

Male and Female

Key inclusion criteria

Advanced rectal cancer diagnosed by colonoscopy, CT or MRI imaging

Key exclusion criteria

Patient unable to give consent

Target sample size

10


Research contact person

Name of lead principal investigator

1st name Kenji
Middle name
Last name Matsuda

Organization

Wakayama medical university

Division name

2nd department of surgery

Zip code

641-8509

Address

811-1 Kimiidera Wakayama, Japan

TEL

073-441-0613

Email

m07055nt@wakayama-med.ac.jp


Public contact

Name of contact person

1st name Norio
Middle name
Last name Takemoto

Organization

Wakayama medical university

Division name

2nd department of surgery

Zip code

641-8509

Address

811-1 Kimiidera Wakayama, Japan

TEL

073-441-0613

Homepage URL


Email

m07055nt@wakayama-med.ac.jp


Sponsor or person

Institute

Wakayama medical university

Institute

Department

Personal name



Funding Source

Organization

Research expense

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Wakayama medical university

Address

811-1 Kimiidera Wakayama, Japan

Tel

0734472300

Email

wa-rinri@wakayama-med.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2021 Year 09 Month 02 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2021 Year 03 Month 26 Day

Date of IRB

2021 Year 04 Month 26 Day

Anticipated trial start date

2021 Year 04 Month 27 Day

Last follow-up date

2026 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Nothing


Management information

Registered date

2021 Year 09 Month 02 Day

Last modified on

2024 Year 02 Month 01 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000051790


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name